Clinical trials: Age Related Maculopathy
Neovascular Age-Related Macular Degeneration (nAMD)
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up…
- Trial name
- SHASTA (NCT04746963)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Retinal Degeneration, Retinal Diseases
SGLT2 Inhibitors in Geographic Atrophy
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration.
- Conditions
- Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy
- Trial name
- NCT07174687
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Washington University School of Medicine
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
- Trial name
- ARCHER II (NCT06510816)
- Testing
- Vonaprument
- Where
- 132 sites in United States, Australia and 12 more
- Volunteers
- 659 people
- Sponsor
- Annexon, Inc.
Age-related Macular Degeneration
Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann
Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50. Neovascular AMD, the most serious and severe form, is characterized by the appearance, spread and growth of subretinal new vessels.
- Trial name
- NCT04891835
- Testing
- Data extraction from medical files
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Laurence Postelmans
Age-related Macular Degeneration (AMD)
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
The purpose of this first-in-human study is to evaluate the safety and tolerability of single ascending doses of LMG324 to determine the maximum tolerated dose (MTD) in neovascular age-related macular degeneration (nvAMD)…
- Trial name
- NCT02398500
- Testing
- LMG324, Ranibizumab 0.5 mg
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or…
- Trial name
- NCT00134667
- Testing
- Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium)
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Eyetech Pharmaceuticals
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting…
- Trial name
- NCT04480463
- Testing
- SCD411, Aflibercept
- Where
- 130 sites in United States, Australia and 12 more
- Volunteers
- 576 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Wet Age-related Macular Degeneration (wAMD)
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD.
- Trial name
- NCT06718816
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
Exudative Macular Degeneration
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during…
- Trial name
- NCT02287298
- Testing
- TRIPLE COMBINATION THERAPY
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- The Retina Center of St. Louis County, PC
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization…
- Trial name
- NCT00511706
- Testing
- dexamethasone, ranibizumab
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 243 people
- Sponsor
- Allergan
Age-Related Macular Degeneration
Removal of Massive Subretinal Organized Blood Clot With Fragmatome
By using the ultrasound power delivered by fragmatome, the hard, organized blood clot could be removed easily.
- Trial name
- NCT04196049
- Testing
- fragmatome
- Where
- Taiwan
- Volunteers
- 3 people
- Sponsor
- Changhua Christian Hospital
Age-Related Macular Degeneration
Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration
This open-label, randomized, Phase II research study will look to see whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as…
- Trial name
- NCT00805233
- Testing
- combination ranibizumab + bromfenac, ranibizumab injection alone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oregon Health and Science University
Age-related Macular Degeneration, Retinal Vein Occlusion
Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections
Evaluation if a computer-based tutorial ("MacInfo" tool) improves the patients' knowledge about intravitreal drug injections, associated risks, and the underlying diseases of treatment-naive patients.
- Conditions
- Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT04142164
- Testing
- MacInfo presentation
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Prim. Prof. Dr. Oliver Findl, MBA
Age Related Maculopathy
Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation for Two More Years (LUTEGA 2)
The primary objective of LUTEGA 2 is it to determine the long term effect (about 2 more years after LUTEGA 1, NCT00763659) of the supplementation with a fixed combination of lutein/zeaxanthin and omega-3- fatty acids in two…
- Trial name
- NCT01648660
- Testing
- Lutein/ Zeaxanthin + Omega- 3- Fatty Acids
- Volunteers
- 80 people
- Sponsor
- University of Jena
Neovascular Age-Related Macular Degeneration
Russian Registry of Patients With nAMD
A three-year, non-randomized, observational, multicenter prospective nAMD study - patient registry.
- Trial name
- NCT04935411
- Testing
- nAMD
- Where
- Russia
- Volunteers
- 2,665 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD
Neovascular Age-Related Macular Degeneration (NV AMD) remains the leading cause of vision loss among people over 65. Intravitreal injections with drugs that block VEGF have revolutionized treatment of NV AMD.
- Trial name
- NCT02367365
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Duke University
Age Related Macular Degeneration
Visual Function Tests in Age-related Macular Degeneration
The goal of this study is to assess a battery of visual function tests in subjects with non-exudative age-related macular degeneration
- Trial name
- NCT03275753
- Testing
- Visual Function Tests
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Age-related Macular Degeneration (AMD)
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
The purpose of this study is to assess whether switching nAMD patients from aflibercept to brolucizumab would permit extension of treatment intervals while maintaining treatment efficacy, thereby alleviating the treatment burden…
- Trial name
- PEREGRINE (NCT04697953)
- Testing
- brolucizumab
- Sponsor
- Novartis Pharmaceuticals
Geographic Atrophy
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD.
- Trial name
- NCT03295877
- Testing
- RO7171009
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- Genentech, Inc.
Eye Diseases
Study for Collection of Aflibercept Data in Routine Practice
The French CODEX study is designed as a national database to describe, in routine medical practice, functional and anatomical responses to intravitreal Aflibercept injection, in a large population of anti-VGEF-naïve patients…
- Trial name
- CODEX (NCT02811692)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 425 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.